Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans

José M. Vicencio(Breast Cancer Now), Tony Ng(King's College London)
Cell Death and Disease
March 28, 2022
Cited by 30


Related Papers